Arcturus Therapeutics (ARCT) Set to Announce Earnings on Thursday

Key Points

• Arcturus Therapeutics is scheduled to report Q3 2026 earnings after the market closes on November 5. Analysts expect a loss of $0.68 per share and revenue of approximately $8.0 million.
• In its previous quarter, the biotechnology company reported an adjusted loss of $0.84 per share, beating estimates, while revenue of $2.96 million fell short of expectations. Analysts project full-year and next-year losses of $3.48 and $3.59 per share, respectively.
• ARCT shares opened at $12.07, with the stock up 7.5% and trading below the analyst consensus target of $22.29. Wall Street’s overall rating is “Moderate Buy,” although recommendations range from “strong buy” to “sell.”

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) is expected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Arcturus Therapeutics to announce earnings of ($0.6804) per share and revenue of $8.00 million for the quarter. Investors may review the information on the company's upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.16. The company had revenue of $2.96 million for the quarter, compared to the consensus estimate of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative return on equity of 46.54%. On average, analysts expect Arcturus Therapeutics to post ($3.48) EPS for the current fiscal year and ($3.59) EPS for the next fiscal year.

Arcturus Therapeutics Stock Up 7.5%

Shares of Arcturus Therapeutics stock opened at $12.07 on Thursday. The stock has a market cap of $343.07 million, a PE ratio of -3.65 and a beta of 2.48. The business has a fifty day simple moving average of $13.57 and a 200-day simple moving average of $8.95. Arcturus Therapeutics has a 12 month low of $5.50 and a 12 month high of $17.96.

Wall Street Analyst Weigh In

ARCT has been the topic of several recent analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Arcturus Therapeutics in a research report on Thursday, October 15th. Roth Capital reissued a "buy" rating and issued a $41.00 price objective on shares of Arcturus Therapeutics in a research note on Wednesday, September 2nd. BTIG Research decreased their price objective on Arcturus Therapeutics from $23.00 to $20.00 and set a "buy" rating for the company in a research report on Thursday, September 24th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Finally, Zacks Research raised Arcturus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $22.29.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company's platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company's development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.